Biohaven Appoints Vlad Coric M.D. as Chief Executive

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Biohaven Appoints Vlad Coric M.D. as Chief Executive Officer

NEW HAVEN, Conn., Nov. 19, 2015 (GLOBE NEWSWIRE) -- via PRWEB - The Board of Directors of Biohaven Pharmaceutical Holding Company Limited (d/b/a Biohaven) is pleased to announce the election of Vlad Coric, M.D. as Chief Executive Officer. Dr. Coric has had a distinguished academic and pharmaceutical career with more than 15 years of drug discovery and clinical development experience at Yale University School of Medicine and Bristol-Myers Squibb.

Within the pharmaceutical industry, Dr. Coric has worked across therapeutic areas including neuroscience, oncology, immuno-oncology and virology. He has been involved in multiple research and development programs including marketed drugs such as ABILIFY® (aripiprazole; partial dopamine agonist), OPDIVO® (nivolumab; anti-PD1), YERVOY® (Ipilimumab; anti-CTLA-4), DAKLINZA® (daclatasvir; NS5A inhibitor) and SUNVEPRA® (asunaprevir; NS3 inhibitor). Most recently at Bristol-Myers Squibb, Dr. Coric was the Neuro-Oncology Indication Lead for Immuno-Oncology where he spearheaded the design of and led the first global registrational trial using checkpoint inhibitors in glioblastoma. As an Associate Clinical Professor at Yale, he served as Chief of the Yale Clinical Neuroscience Research Unit, managing innovative research trials for patients with treatment-refractory illnesses. He has published widely with more than 50 peer-reviewed publications and numerous presentations at scientific meetings. Dr. Coric was the also first to report the therapeutic effects of the glutamate-modulating agent riluzole in neuropsychiatric disorders and led the first clinical trial employing cerebrospinal fluid biomarkers to identity and enrich for patients with Prodromal Alzheimer's Disease while at Bristol-Myers Squibb.

Declan Doogan M.D. Chairman of Biohaven stated, "On behalf of Biohaven, I am delighted to make this appointment. Vlad is a significant figure in the fields of neuroscience research and drug development. His entrepreneurial and drug development credentials make him an ideal candidate to build Biohaven into a premier company in the glutamatergic space."

Dr. Coric commented, "It is a privilege to join the Biohaven team -- this represents the culmination of many years of research combining my work in the glutamatergic system with broad drug development experience. I have been extremely fortunate to be part of highly effective and innovative research teams at both Yale and Bristol-Myers Squib. I look forward to helping Biohaven bring innovative treatments to patients suffering from treatment-resistant disorders."

Drugs that modulate glutamate neurotransmission have therapeutic application in numerous diseases where aberrations in glutamate function have been implicated, including amyotrophic lateral sclerosis (ALS), spinocerebellar ataxia, Alzheimer's disease, neurodevelopmental disorders, cancer, anxiety disorders and treatment resistant- depression.

"Over the near term, Biohaven's focus will be to quickly advance our late stage glutamate modulating agents into the clinic and then expand with additional potential indications across disease states including some orphan illnesses. Rather than focus on one illness, we will leverage our expertise in the glutamatergic system and follow the science across diseases where there is a strong mechanistic basis for modulation of this important system," Dr. Coric added.

Dr. Coric completed his internship at Yale-New Haven Hospital and his residency and fellowship training in the Department of Psychiatry at the Yale University School of Medicine. Dr. Coric earned his medical degree at Wake Forest University School of Medicine in North Carolina and his undergraduate Bachelor of Science degree at the University of Connecticut where he was an Honors Scholar in Physiology and Neurobiology. He also has previous entrepreneurial experience founding multiple businesses, and has been in involved in professional activities including serving as President of the Connecticut Psychiatric Society (an 800-member district branch of the American Psychiatric Association).

About Biohaven

Biohaven is a privately-held biopharmaceutical company engaged in the identification and development of clinical stage compounds targeting the glutamatergic system. The company has licensed intellectual property from Yale University and Massachusetts General Hospital. Biohaven is owned by a group of investors including Portage Biotech Inc. (OTC Market: PTGEF, Canadian Securities Exchange: PBT.U), Yale University and other private investors. The company's first drug candidate, BHV-0223, is a novel formulation of a glutamate-modulating agent, being developed under FDA 505(b)(2) guidelines. BHV-4157, a prodrug form of the same glutamate modulating agent, is being developed as a New Chemical Entity (NCE). The FDA cleared the company's Investigational New Drug application (IND) in August 2015 and BIOHAVEN has completed a PK study in humans with the final study report expected by 4Q2015 to enable the Phase 2/3 start in 2016. The company plans to advance other glutamatergic approaches and is actively exploring licenses for additional compounds.

For further information, contact Dr. Declan Doogan, the Chairman at Declan.doogan(at)biohavenpharma(dot)com.

Forward-Looking Statements This news release includes forward-looking statements within the meaning of the U.S. federal and Canadian securities laws.  These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of the Company's management. All statements, other than statements of historical facts, included in this press release regarding the Company's plans and objectives, expectations and assumptions of management are forward-looking statements. The use of certain words, including the words "estimate," "project," "intend," "expect," "believe," "anticipate," "will, "plan," "could," "may" and similar expressions are intended to identify forward-looking statements. The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements and you should not place undue reliance on the Company's forward-looking statements. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements including receipt of regulatory approvals and market conditions. The forward-looking statements are made as of this date and the Company does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

This article was originally distributed on PRWeb. For the original version including any supplementary images or video, visit http://www.prweb.com/releases/2015/11/prweb13091996.htm

Biohaven Pharmaceutical Holding Company Limited Dr. Declan Doogan, Chairman +1 203-314-5352

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pony.ai & Toyota Launch 1,000 Gen-7 Robotaxis in China

Updated Category News Views 74

Revving Up the Autonomous Ride Revolution Not every day you see two giants, Pony.ai and Toyota, join forces to shake up the way folks get from A to B. But here we are — they’ve fired up their engines in Guangzhou, unleashing their Gen-7 bZ4X Robotaxis for commercial use. And let me tell you, this is no shot in the dark. With plans to dot about 1,000 of these...

Continue Reading
SOBER CAFFEINE™: Modern Energizer Without the Bull

Updated Category News Views 37

Shed the Cans and Embrace Convenience I'm sure you've had a run-in with the standard energy drink routine. You know, the massive cans, a gut punch of sugar, and the inevitable crash that follows? Sobriety Supplements LLC decided enough is enough and rolled out something that just makes sense—SOBER CAFFEINE™ capsules. This little pill is a godsend for folks sick of...

Continue Reading
Ampace Focuses on Battery Safety Standards at RE+ 2026

Updated Category News Views 113

Battery Safety Takes Center Stage No mystery here: the safety of our beloved lithium-ion batteries is crucial, especially as AI data centers sprout like weeds. At RE+ 2026, Ampace is putting its chips on the table by spotlighting this hot topic. Dr. Drew Feng, their Chief Safety Officer, is set to reveal the big guns: findings from the PU100 large-scale fire test. Mark...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 275

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
FFR's Michigan Milestone and Major Robotics Update

Updated Category News Views 160

Nobody's going to argue that breaking into new territories isn't a gamble, but sometimes you just need to roll the dice. FF EAI Robotics Ecosystem Inc. (NASDAQ: FFR) is banking on their move with Aegis Ultra robots, making an academic splash at Central Michigan University. This isn't just about ticking off another state; it's about stacking the deck with new...

Continue Reading
Viking Ventures: Impacts of VK2735 on Obesity Examined

Updated Category News Views 292

Viking Therapeutics Reveal Surprising Data on VK2735 The latest from Viking Therapeutics' camp is giving obesity some serious food for thought, with new data making waves at the ObesityWeek® 2026 meeting. Their investigational dual agonist, VK2735, seems to be shaking things up, as early phase clinical data shows an impressive 74% of participants managed to improve at...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 308

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 431

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 407

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 421

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading

Top 5 Most Recently Viewed Articles

Daniel Pink on Leadership and Workplace Evolution Insights

Updated Category News Views 424

Exploring Leadership in a Changing Workplace The recent episode of Info-Tech Research Group's podcast, Digital Disruption, highlights a thought-provoking discussion with bestselling author Daniel Pink, focusing on how leaders can adapt in a time he describes as 'the great sort'. This term encapsulates the ongoing transformation in our approach to work, leadership, and the...

Continue Reading
MORSE Corp's Community Cleanup Initiative: Making an Impact

Updated Category News Views 240

MORSE Corp's Commitment to Community Service MORSE Corp recently dedicated an entire day to community service by hosting a cleanup initiative at local beaches and parks. On a beautiful Wednesday, the organization mobilized its team to gather at a coastal spot to improve the environment and promote community spirit. This initiative is part of their annual effort to...

Continue Reading
FDA's New Proposal to Enhance Nutrition Awareness on Food Labels

Updated Category News Views 125

Revolutionizing Nutrition Transparency for Consumers Today, the U.S. Food and Drug Administration (FDA) is taking significant steps towards improving consumer awareness about the nutritional value of packaged foods. A new proposal dictates that most packaged foods will require a prominent front-of-package (FOP) nutrition label. This initiative is part of a broader...

Continue Reading
CW Bancorp Declares Quarterly Dividend for Shareholders

Updated Category News Views 150

CW Bancorp Announces Dividend Declaration CW BANCORP (OTCQX: CWBK), the parent company of CommerceWest Bank, has approved a quarterly cash dividend. The news comes as the company continues to prioritize shareholder value while supporting its growth journey. Details of the Cash Dividend The Board of Directors of CW Bancorp declared a cash dividend of $0.23 per common...

Continue Reading
Universal Electronics Unveils QuickSet homeSense at CES Event

Updated Category News Views 348

Universal Electronics Introduces QuickSet homeSense Technology Universal Electronics Inc. (NASDAQ: UEIC) has made headlines by launching its innovative QuickSet homeSense technology. This introduction took place at the prestigious International Consumer Electronics Show (CES) where the spotlight is often on groundbreaking tech. UEI, a leader in wireless control solutions,...

Continue Reading